

How to Prescribe Jakafi[™]

Jakafi is available through a limited network of Specialty Pharmacies. The IncyteCARES program was created to facilitate patient access to Jakafi and is available toll-free for all healthcare providers, patients and their caregivers at 1-855-4-Jakafi (855-452-5234).

Please follow these steps to successfully prescribe Jakafi for your patients:

Step 1: Complete the Program Enrollment Form

Both you and the patient complete and sign, then FAX the one-page Jakafi Enrollment Form to IncyteCARES at 1-855-525-7207. This form will serve as the patient's initial prescription for Jakafi. Be sure to have the patient check the enrollment boxes for both the Access and Reimbursement Services and the Education and Support Services, if they would like to participate in these services.

Step 2: Insurance Verification

The IncyteCARES program will confirm your patient's insurance coverage. Once verified, your patient's prescription will be sent to a Specialty Pharmacy. Through IncyteCARES a comprehensive co-payment assistance and free-drug program is available for eligible patients.*

Step 3: Medication sent from a Specialty Pharmacy

Your patient will be assigned to a Specialty Pharmacy that provides the lowest patient out-of-pocket cost for Jakafi. The Specialty Pharmacy will collect co-payments, provide refill reminders, and ship Jakafi directly to your patient.

^{*}Co-pay assistance program not available in all states or for patients who are receiving prescription reimbursement under any federal, state, or government-funded programs. Enrollment necessary.

RUX-1066b



IncyteCARES Program Connecting to Access, Reimbursement, Education and Support

P.O. Box 221798 • Charlotte, NC 28222-1798 • Phone: 1-855-4-Jakafi (855-452-5234) • Fax: 1-855-525-7207

IncyteCARES offers two services: 1.) Access and Reimbursement services assist patients starting on JakafiTM (ruxolitinib) 2.) Education and Support services encourage patients to stay on Jakafi

Ph	ysician Information
Physician Name:	
Site/Facility Name:	
Street Address:	
City:	State: Zip:
Office Contact:	Telephone:
Fax:	Best Time to Call:
Office Contact E-mail:	
State License #:	Payer Specific ID#:
Tax ID #:	NPI #:
Patient Clinica	al Information (Please complete A - D)
A) Patient Diagnosis / IC	D-9 Code:
-	with myeloid metaplasia 🛛 🛛 289.83 Myelofibrosi
Other diagnosis:	
R) Doos the nationt have	e intermediate or high-risk myelofibrosis?
\square Yes \square No	e internetiate of ingli-fisk ingelofibiosis?
C) Previous or Current N	
C) Previous or Current N Does this patient have o	r has had any previous MF therapies?
C) Previous or Current N Does this patient have o ☐ Yes:	r has had any previous MF therapies?
 C) Previous or Current N Does this patient have o □ Yes: D) Contact for IncyteCA 	r has had any previous MF therapies? No RES to call to discuss this patient's therapy?
 C) Previous or Current N Does this patient have o □ Yes: D) Contact for IncyteCA Name 	r has had any previous MF therapies?
 C) Previous or Current N Does this patient have o □ Yes: D) Contact for IncyteCA 	r has had any previous MF therapies?
 C) Previous or Current N Does this patient have o □ Yes: D) Contact for IncyteCA Name 	r has had any previous MF therapies?
 C) Previous or Current N Does this patient have o Yes: D) Contact for IncyteCAI Name	r has had any previous MF therapies?
 C) Previous or Current N Does this patient have o Yes: D) Contact for IncyteCAI Name	r has had any previous MF therapies?
 C) Previous or Current N Does this patient have o Dest this patient have o Yes:	r has had any previous MF therapies? □ No RES to call to discuss this patient's therapy? at () – MSN, PA, NP) Prescription e coverage (or the patient's approval for assistance through Id be shipped via a specialty pharmacy provider to the above, right) unless otherwise indicated by practitioner: Date:
 C) Previous or Current N Does this patient have o Dest this patient have o Yes:	r has had any previous MF therapies? □ No RES to call to discuss this patient's therapy? at () MSN, PA, NP) Prescription e coverage (or the patient's approval for assistance through Id be shipped via a specialty pharmacy provider to the above, right) unless otherwise indicated by practitioner:
C) Previous or Current M Does this patient have o ☐ Yes: D) Contact for IncyteCAI Name Title (eg, MD, RN, BSN, M Upon confirmation of insurance the Program), medication shoul patient's home address (listed a Patient Name: Product Name:Jakafi [™] (r has had any previous MF therapies? □ No RES to call to discuss this patient's therapy? at () – MSN, PA, NP) Prescription e coverage (or the patient's approval for assistance through Id be shipped via a specialty pharmacy provider to the above, right) unless otherwise indicated by practitioner: Date:
C) Previous or Current M Does this patient have o ☐ Yes: D) Contact for IncyteCAI Name Title (eg, MD, RN, BSN, M Upon confirmation of insurance the Program), medication shoul patient's home address (listed a Patient Name: Product Name: Jakafi [™] (Dosage: ☐ 5 mg ☐ 10 mg	r has had any previous MF therapies? □ No RES to call to discuss this patient's therapy? at () MSN, PA, NP) Prescription e coverage (or the patient's approval for assistance through Id be shipped via a specialty pharmacy provider to the above, right) unless otherwise indicated by practitioner: Date:
C) Previous or Current M Does this patient have o ☐ Yes:	r has had any previous MF therapies? □ No RES to call to discuss this patient's therapy? at () MSN, PA, NP) Prescription e coverage (or the patient's approval for assistance through Id be shipped via a specialty pharmacy provider to the above, right) unless otherwise indicated by practitioner: Date: (ruxolitinib) g □ 15 mg □ 20 mg □ 25 mg
C) Previous or Current M Does this patient have o ☐ Yes:	r has had any previous MF therapies? □ No RES to call to discuss this patient's therapy? at () MSN, PA, NP) Prescription e coverage (or the patient's approval for assistance through Id be shipped via a specialty pharmacy provider to the above, right) unless otherwise indicated by practitioner: Date: (ruxolitinib) g □ 15 mg □ 20 mg □ 25 mg Quantity:

I verify that the patient and physician information contained in this enrollment form is complete and accurate to the best of my knowledge and that I have prescribed Jakafi based on my professional judgment of medical necessity.

I represent and warrant that I have my patient's authorization on file to disclose their health information and to transfer such authorization to Incyte and its agents to use and disclose such information as necessary to provide reimbursement services and to forward this prescription to a dispensing pharmacy on behalf of my patient.

I appoint IncyteCARES solely to convey on my behalf to the pharmacy chosen by or for the above-named patient, the prescription described herein.

I authorize IncyteCARES to perform a preliminary assessment of insurance verification for the above-named patient, and I further authorize and request that the Program provide to me any and all information necessary for completing a Letter of Medical Necessity as may be required as a result of such insurance verification assessment.

Physician Signature:

Date: ____ / ___ /

Please fax to 855-525-7207

Jakafi is a trademark of Incyte Corporation.	
© 2012, Incyte Corporation. All rights reserved.	RUX-1111

A Patient Information		
Patient Name:		
Shipping Address:		
City:	State:	Zip:
Date of Birth:	SSN:	
Phone Number:	Best Tir	ne to Call:
Alternate Phone Number:		
Primary Language:		
E-mail Address:		
Alternate Contact and Phone		

Patient Insurance Information

Primary Rx Insurer: _____

Telephone: _____ Policy ID Number:

Subscriber Name/Date of Birth:

Secondary Rx Insurer: _____

Telephone: _____ Policy ID Number:

Policy ID Number: _____ Group Number: ____ Subscriber Name/Date of Birth:

Please include a photocopy of the patient's insurance card(s), if possible.

Group Number:



B

Patient Financial Information*

Current annual household income: \$ ____

Number of household members dependent on income stated above (include applicant):

"If you would like to be considered for co-pay or product support please provide income information for potential eligibility determination. If approved for support, documentation (latest tax return or W2 or one month of pay stubs) will be required within 90 days.

D Patient Authorization for the IncyteCARES Program

Access and Reimbursement Services

I understand my physician has authorized IncyteCARES to request a benefits verification to determine if my prescription for Jakafi is covered under my health insurance. I have requested that IncyteCARES determine my eligibility for co-pay assistance or free drug. If IncyteCARES needs to verify my financial or insurance information, I authorize my healthcare providers or my insurance company to disclose information about me.

I understand that any co-pay assistance or free drug provided to me through IncyteCARES is contingent upon meeting certain eligibility criteria and that Incyte has the right at any time, and without notice, to modify or discontinue IncyteCARES or any assistance provided to me.

I understand that I can cancel this authorization at any time by writing to IncyteCARES at the address above. If I cancel this authorization, then my healthcare providers and my insurance company will not provide any further information about me, and IncyteCARES will no longer provide me with assistance.

I understand that once IncyteCARES receives information about me, federal privacy laws may no longer apply. I also understand that IncyteCARES will only use or disclose information about me to operate the Program and provide services to me or to assist me in finding alternative sources of funding or coverage for my treatment.

I understand that I do not have to sign this authorization to obtain treatment or seek payment for treatment on my own; however, in order to be eligible for the services provided by IncyteCARES I must sign the authorization.

Education and Support Services

Lauthorize Incyte and affiliated companies to use and release information about me to its agents working on its behalf for the purposes of providing education and ongoing support services to me for Jakafi. I authorize Incyte to use and give out my information, send me materials related to Jakafi or other information in which I might be interested, and to contact me by e-mail, mail, or phone on occasion regarding these services or for feedback about Jakafi, or as required or permitted by law.

I acknowledge that I am a resident of the United States and verify that the information provided in this enrollment form is current, complete, and accurate.

This authorization expires in ten (10) years.

01/12

I WISH TO BE ENROLLED AS FOLLOWS BY CHECKING	THE APPROPRIATE BOX(ES)
ACCESS AND REIMBURSEMENT SERVICES	EDUCATION AND SUPPORT SERVICES
By signing below I authorize IncyteCARES to contact me and notify me regarding my benefits	
Patient Signature:	Date://
Legal Guardian or Representative Signature:	Date: //
Relationship to Patient:	



IncyteCARES Program Enrollment Instructions For Providers

The left-hand side of the form contains physician information needed for enrollment and physician must sign.

Physician Information Physician Name: Lisa Smith, MD Site/Facility Name: Community Practice Providers, Inc Street Address: 3720 River Road, Suite 500 City: Springfield State: IL_Zip: 62701 Office Contact: Christy Jones Telephone: (555) 111-2222 Fax: (555) 111-3333 Best Time to Call: Before 2 PM Office Contact E-mail: cjones@cpp.com	Step 1 Physician Information Include practice contact information, office staff contact and any payer-specific provider ID number relevant for the patient's insurance to facilitate quick and effective contact with the payer and your office. Please write legibly or type information, if possible.
State License #: 12345 Payer Specific ID#: 09876 Tax ID #: 45678 NPI #: 0101010 2 Patient Clinical Information (Please complete A - D)	Patient Clinical Information This section is required and could delay the
 A) Patient Clinical information (Please complete A - D) A) Patient Diagnosis / ICD-9 Code: 238.76 Myelofibrosis with myeloid metaplasia Other diagnosis: B) Does the patient have intermediate or high-risk myelofibrosis? B) Does the patient have intermediate or high-risk myelofibrosis? C) Previous or Current Myelofibrosis Therapies: Does this patient have or has had any previous MF therapies? Yes: Yes: Xo D) Contact for IncyteCARES to call to discuss this patient's therapy? Name Lisa Smith Title (eg, MD RN, BSN, MSN, PA, NP) 	 verification process if not completed. This information will help with enrollment into copay assistance and/or prior authorization assistance. Please complete A - D: A) Patient's diagnosis B) Indicate if the patient has intermediate or high-risk myelofibrosis according to the IWG criteria C) Previous or current myelofibrosis therapy (this may be substituted with last chart note) D) If a program oncology nurse needs to discuss patient clinical information with the office, please include whom they should speak with and their contact information.
3 Prescription Upon confirmation of insurance coverage (or the patient's approval for assistance through the Program), medication should be shipped via a specialty pharmacy provider to the patient's home address (listed above, right) unless otherwise indicated by practitioner: Patient Name: Richard Simons Date: 01/01/12 Product Name: Jakafi [™] (ruxolitinib) Date: 01/01/12 Dosage: 5 mg 10 mg 15 mg 20 mg 25 mg Sig: Twice a day Quantity:60 60 Refill(s): 12 DEA #:999333000 Ship to: Image: Patient's home Doctor's office Is there a preferred Specialty Pharmacy? No	Step 3PrescriptionInclude patient name, dosage, quantity, refills, DEA # and date to complete the prescription. A separate prescription is not needed.Please check the box to indicate if Jakafi should be shipped to the patient's home or the doctor's office.
4 Physician Declaration	

I verify that the patient and physician information contained in this enrollment form is complete and accurate to the best of my knowledge and that I have prescribed Jakafi based on my professional judgment of medical necessity.

I represent and warrant that I have my patient's authorization on file to disclose their health information and to transfer such authorization to Incyte and its agents to use and disclose such information as necessary to provide reimbursement services and to forward this prescription to a dispensing pharmacy on behalf of my patient.

I appoint IncyteCARES solely to convey on my behalf to the pharmacy chosen by or for the above-named patient, the prescription described herein.

I authorize IncyteCARES to perform a preliminary assessment of insurance verification for the above-named patient, and I further authorize and request that the Program provide to me any and all information necessary for completing a Letter of Medical Necessity as may be required as a result of such insurance verification assessment.

Physician Signature: Lisa Smith

Date: 01 / 01 / 2012

Please fax to 855-525-7207

Jakafi is a trademark of Incyte Corporation. © 2012, Incyte Corporation. All rights reserved.

RUX-1111a

Physician Declaration

A physician signature is required in order for IncyteCARES to perform a benefit verification.

Completed forms can be faxed to 1-855-525-7207 or mailed to IncyteCARES program P.O. Box 221798 Charlotte, NC, 28222-1798

1/12

Step 4



IncyteCARES Program Enrollment Instructions For Patients/Caregivers

The right-hand side of the form contains patient information needed for enrollment and the patient must sign.

5	A Patient Information
	Patient Name: Richard Simons
Patient Contact Information	Shipping Address: 1234 Green Tree Road
	City: Small Town State: IL Zip: 62700
Include patient and alternate contact name and	
relationship, with alternate phone numbers and Step 1	Phone Number: (555) 100-5000 Best Time to Call: Early Evening
best time to call, so the program can call to	Alternate Phone Number: (555) 200-6000
discuss benefits and the specialty pharmacy can	Primary Language: English
call to schedule delivery.	E-mail Address: <u>Richard@email.com</u>
	Alternate Contact and Phone Number: Betty Simons (wife), (555) 100-5001
	B Patient Insurance Information
Patient Rx Insurance Information	Primary Rx Insurer: <u>Rx Insurance Co.</u> Telephone: <u>(630)</u> 444-0000
	Policy ID Number: <u>65432</u> Group Number: <u>77777</u>
Include patient's Rx insurance information: Rx	Subscriber Name/Date of Birth: Richard Simons, 08/24/67
plan name, ID, group # and phone # to facilitate contact with the patient's Rx insurance company Step 2	
· contact that the patients fix insurance company	
to verify benefits. Please include a photocopy of	Telephone: (630) 555-1111 Policy ID Number: 99999 Group Number: 55555
the Rx insurance card(s), if possible.	Subscriber Name/Date of Birth: Betty Simons, 04/22/71
Financial Information	Please include a photocopy of the patient's insurance card(s), if possible.
	C Patient Financial Information*
Include current annual household income and the	Current annual household income: \$ _78,000
number of dependents (including patient) if the	Number of household members dependent on income stated above
patient would like to be considered for copay or Step 3	(include applicant): <u>3</u>
free drug assistance.	*If you would like to be considered for co-pay or product support please provide
	income information for potential eligibility determination. If approved for support, documentation (latest tax return or W2 or one month of pay stubs) will be
Patients will be temporarily approved if they meet	required within 90 days.
the eligibility requirements but must provide	D Patient Authorization for the IncyteCARES Program
income documentation (latest tax return, W2, or	
one month of pay stubs) within 90 days to remain	Access and Reimbursement Services I understand my physician has authorized IncyteCARES to request a benefits verification to determine if my
	prescription for Jakafi is covered under my health insurance. I have requested that IncyteCARES determine my eligibility for co-pay assistance or free drug. If IncyteCARES needs to verify my financial or insurance information,
eligible for assistance.	eligibility for co-pay assistance or free drug. If IncyteCARES needs to verify my financial or insurance information, I authorize my healthcare providers or my insurance company to disclose information about me.
	I understand that any co-pay assistance or free drug provided to me through IncyteCARES is contingent upon meeting certain eligibility criteria and that Incyte has the right at any time, and without notice, to modify or
Detient Authorization for the Dreaman	discontinue IncyteCARES or any assistance provided to me.
Patient Authorization for the Program	I understand that I can cancel this authorization at any time by writing to IncyteCARES at the address above. If I cancel this authorization, then my healthcare providers and my insurance company will not provide any further
Include patient or guardian signature and date.	information about me, and IncyteCARES will no longer provide me with assistance.
Signature is required in order for IncyteCARES to	I understand that once IncyteCARES receives information about me, federal privacy laws may no longer apply. I also understand that IncyteCARES will only use or disclose information about me to operate the Program and
	provide services to me or to assist me in finding alternative sources of funding or coverage for my treatment.
contact the patient with the results of the benefits Step 4	I understand that I do not have to sign this authorization to obtain treatment or seek payment for treatment on my own; however, in order to be eligible for the services provided by IncyteCARES I must sign the authorization.
verification.	Education and Support Services
	I authorize Incyte and affiliated companies to use and release information about me to its agents working on its behalf for the purposes of providing education and ongoing support services to me for Jakafi. I authorize Incyte
Check the applicable boxes to be considered for	to use and give out my information, send me materials related to Jakafi or other information in which I might be interested, and to contact me by e-mail, mail, or phone on occasion regarding these services or for feedback about
co-pay and free drug assistance and to enroll in	Jakafi, or as required or permitted by law.
the patient education and support services.	I acknowledge that I am a resident of the United States and verify that the information provided in this enrollment form is current, complete, and accurate.
•	This authorization expires in ten (10) years.
	I WISH TO BE ENROLLED AS FOLLOWS BY CHECKING THE APPROPRIATE BOX(ES)
	ACCESS AND REIMBURSEMENT SERVICES
Completed forms can be faxed to 1-855-525-7207 or mailed to	By signing below I authorize IncyteCARES to contact me and notify me regarding my benefits
IncyteCARES program P.O. Box 221798 Charlotte, NC, 28222-1798	Patient Signature: Richard Simons Date: 01 / 01 / 2012
	Legal Guardian or Representative Signature:/Date:/Date:/
	Relationship to Patient: <u>N/A</u>

1/12